share_log

D. Boral Capital Initiates Coverage On Lineage Cell Therapeutics With Buy Rating, Announces Price Target of $3

D. Boral Capital Initiates Coverage On Lineage Cell Therapeutics With Buy Rating, Announces Price Target of $3

D. Boral Capital对lineage cell therapeutics启动了覆盖,给予买入评级,宣布目标价为3美元。
Benzinga ·  11/18 10:12  · 评级/大行评级

D. Boral Capital analyst Jason Kolbert initiates coverage on Lineage Cell Therapeutics (AMEX:LCTX) with a Buy rating and announces Price Target of $3.

D. Boral Capital 分析师Jason Kolbert对lineage cell therapeutics (美交所:LCTX)启动覆盖,给予 买入 评级,并宣布目标价格为3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发